Literature DB >> 29977663

Genetic Modifiers in Neurodegeneration.

Nimansha Jain1, Alice S Chen-Plotkin1.   

Abstract

PURPOSE OF REVIEW: To review the evidence for genetic modifier effects in the neurodegenerative diseases Huntington's Disease (HD), Frontotemporal Lobar Degeneration (FTLD), Alzheimer's Disease (AD), and Parkinson's Disease (PD). RECENT
FINDINGS: Increasingly, we understand human disease genetics less through the lens of single-locus/single-trait effects, and more through that of polygenic contributions to disease risk. In addition, specific examples of genetic modifier effects of the chromosome 7 gene TMEM106B on various target genes including those causal for Mendelian classes of FTLD - GRN and c9orf72 - have emerged from both genetic cohort studies and mechanistic examinations of biological pathways.
SUMMARY: Here, we summarize the literature reporting genetic modifier effects in HD, FTLD, AD, and PD. We further contextualize reported genetic modifier effects in these diseases in terms of insight they may lend to the concept of a polygenic landscape for the major neurodegenerative diseases.

Entities:  

Keywords:  APOE; Alzheimer’s Disease; FTLD; Genetic modifier; Parkinson’s Disease; TMEM106B; neurodegeneration

Year:  2018        PMID: 29977663      PMCID: PMC6028053          DOI: 10.1007/s40142-018-0133-1

Source DB:  PubMed          Journal:  Curr Genet Med Rep        ISSN: 2167-4876


  107 in total

1.  GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Authors:  Ignacio F Mata; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Debby Tsuang; Haley Huston; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2015-08-21       Impact factor: 10.338

2.  Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?

Authors:  S Lesage; S Belarbi; A Troiano; C Condroyer; N Hecham; P Pollak; E Lohman; T Benhassine; F Ysmail-Dahlouk; A Dürr; M Tazir; A Brice
Journal:  Neurology       Date:  2008-11-04       Impact factor: 9.910

3.  Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Authors:  Yuetiva Deming; Zeran Li; Manav Kapoor; Oscar Harari; Jorge L Del-Aguila; Kathleen Black; David Carrell; Yefei Cai; Maria Victoria Fernandez; John Budde; Shengmei Ma; Benjamin Saef; Bill Howells; Kuan-Lin Huang; Sarah Bertelsen; Anne M Fagan; David M Holtzman; John C Morris; Sungeun Kim; Andrew J Saykin; Philip L De Jager; Marilyn Albert; Abhay Moghekar; Richard O'Brien; Matthias Riemenschneider; Ronald C Petersen; Kaj Blennow; Henrik Zetterberg; Lennart Minthon; Vivianna M Van Deerlin; Virginia Man-Yee Lee; Leslie M Shaw; John Q Trojanowski; Gerard Schellenberg; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Elaine R Peskind; Ge Li; Antonio F Di Narzo; John S K Kauwe; Alison M Goate; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2017-02-28       Impact factor: 17.088

Review 4.  Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease.

Authors:  Soraya Bardien; Suzanne Lesage; Alexis Brice; Jonathan Carr
Journal:  Parkinsonism Relat Disord       Date:  2011-08       Impact factor: 4.891

5.  Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration.

Authors:  Christina M Lang; Katrin Fellerer; Benjamin M Schwenk; Peer-Hendrik Kuhn; Elisabeth Kremmer; Dieter Edbauer; Anja Capell; Christian Haass
Journal:  J Biol Chem       Date:  2012-04-17       Impact factor: 5.157

6.  Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid.

Authors:  T Wisniewski; A Golabek; E Matsubara; J Ghiso; B Frangione
Journal:  Biochem Biophys Res Commun       Date:  1993-04-30       Impact factor: 3.575

7.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

8.  Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease.

Authors: 
Journal:  Cell       Date:  2015-07-30       Impact factor: 41.582

9.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

10.  Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival.

Authors:  Philip Van Damme; Annelies Van Hoecke; Diether Lambrechts; Peter Vanacker; Elke Bogaert; John van Swieten; Peter Carmeliet; Ludo Van Den Bosch; Wim Robberecht
Journal:  J Cell Biol       Date:  2008-03-31       Impact factor: 10.539

View more
  5 in total

Review 1.  Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.

Authors:  Vinod Udayar; Yu Chen; Ellen Sidransky; Ravi Jagasia
Journal:  Trends Neurosci       Date:  2022-01-13       Impact factor: 13.837

Review 2.  Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Jessica Root; Paola Merino; Austin Nuckols; Michelle Johnson; Thomas Kukar
Journal:  Neurobiol Dis       Date:  2021-03-31       Impact factor: 7.046

Review 3.  A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics.

Authors:  Richard N L Lamptey; Bivek Chaulagain; Riddhi Trivedi; Avinash Gothwal; Buddhadev Layek; Jagdish Singh
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

4.  Identification of recurrent genetic patterns from targeted sequencing panels with advanced data science: a case-study on sporadic and genetic neurodegenerative diseases.

Authors:  G Castellani; S Capellari; M Tarozzi; A Bartoletti-Stella; D Dall'Olio; T Matteuzzi; S Baiardi; P Parchi
Journal:  BMC Med Genomics       Date:  2022-02-10       Impact factor: 3.063

5.  Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice.

Authors:  Tuancheng Feng; Shuyi Mai; Jenn Marie Roscoe; Rory R Sheng; Mohammed Ullah; Junke Zhang; Isabel Iscol Katz; Haiyuan Yu; Wenjun Xiong; Fenghua Hu
Journal:  EMBO Rep       Date:  2020-08-10       Impact factor: 8.807

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.